SARS-CoV-2 spike protein conserved peptide epitopes (SARS-CoV-2 S protein conserved epitopes)

SARS-CoV-2 spike protein conserved peptide epitopes are highly stable amino acid sequences within the viral spike (S) protein that exhibit minimal variation across different SARS-CoV-2 variants and other sarbecoviruses (Jaiswal et al., 2023). These epitopes are predominantly located in the S2 subunit, which mediates viral-host membrane fusion, and in specific structural cores of the S1 subunit, such as the receptor-binding domain (RBD) and N-terminal domain (NTD) (Silva et al., 2023). Because these regions are functionally critical and less tolerant of mutations, they serve as ideal targets for the development of universal vaccines and broadly neutralizing monoclonal antibodies (bNAbs) that can maintain efficacy against emerging variants of concern (UB-612 Study, 2023). Therapeutic strategies targeting these epitopes include fusion-inhibiting peptides like EK1 and antibodies like Sotrovimab, which recognize conserved glycan-shielded or structural motifs (NIH, 2023). However, a significant challenge in targeting these regions is their limited accessibility on the native trimer and the risk of molecular mimicry, as some conserved sequences may elicit autoantibodies associated with autoimmune-like symptoms or long COVID (Frontiers in Immunology, 2025).

Other names

SARS-CoV-2 spike protein conserved regionsSARS-CoV-2 S protein universal epitopesPan-coronavirus spike epitopesS2 subunit conserved epitopesSARS-CoV-2 spike protein conserved domainsSARS-CoV-2 S protein conserved peptide sequences

Neutralization of viral entry and inhibition of membrane fusion by targeting functionally critical and mutationally constrained regions of the spike protein (Silva et al., 2023; Jaiswal et al., 2023).